BGM0504
GIP/GLP-1 · s.c. · BrightGene
Summary
- Also known as
- BrightGene
- Mechanism
- GIP/GLP-1
- Route
- s.c.
- Company
- BrightGene
- Highest development stage
- filed
- Status (as of data cut)
- Phase 3 positive in China (52 weeks, up to −19.2 %); NDA accepted (June 2026) verify
- Next milestone
- China approval
Sources for the status
Indications: regulatory and evidence status
| Indication | Code | Status | Evidence |
|---|---|---|---|
| Obesity | 3 positive phase 3 | Positive phase 3 in China; NDA accepted June 2026 | BrightGene NDA announcement (Jun 2026); BGM0504 phase 3 (EASD 2026) |
| T2D | 2 phase 3 ongoing | Phase 3 registered on ClinicalTrials.gov | |
| CV outcomes | 0 no data | ||
| CKD | 0 no data | ||
| HFpEF | 0 no data | ||
| MASH | 0 no data | ||
| Sleep apnoea | 0 no data | ||
| Knee OA | 0 no data | ||
| Alzheimer's | 0 no data |
4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.
Trial arms: weight, HbA1c and tolerability
| Trial | Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BGM0504 phase 2 (China, obesity) | BGM0504 5 mg | obesity china | 24 | — | — | —−10.7 % vs +0.1 % estimand not specified | — | — | — | — | — | — | — | verified |
| BGM0504 phase 2 (China, obesity) | BGM0504 10 mg | obesity china | 24 | — | — | —−16.1 % vs +0.1 % estimand not specified | — | — | — | — | — | — | — | verified |
| BGM0504 phase 2 (China, obesity) | BGM0504 15 mg | obesity china | 24 | — | — | —−18.3 % vs +0.1 % estimand not specified | — | — | — | — | — | — | — | verified |
| BGM0504 phase 3 (obesity) | BGM0504 15 mg | obesity china | 52 | — | — | −19.2 % vs −3.1 % Δ −16.1 pp | — | 0.7 | — | — | — | — | — | verified |
| BGM0504 phase 3 (obesity) | BGM0504 10 mg | obesity china | 52 | — | — | −17.3 % vs −3.1 % Δ −14.2 pp | — | 1.2 | — | — | — | — | — | verified |
| BGM0504 phase 3 (obesity) | BGM0504 5 mg | obesity china | 52 | — | — | −14.3 % vs −3.1 % Δ −11.2 pp | — | 1.7 | — | — | — | — | — | verified |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- BGM0504 5 mg: The abstract reports that no adverse event led to withdrawal from the trial; discontinuation of the study drug is not reported.
- BGM0504 10 mg: The abstract reports that no adverse event led to withdrawal from the trial; discontinuation of the study drug is not reported.
- BGM0504 15 mg: The abstract reports that no adverse event led to withdrawal from the trial; discontinuation of the study drug is not reported.
Verbatim quotes from the source (9)
- BGM0504 15 mg · weight_tp · Results
15 mg: −19.19% (95% CI: −20.63 to −17.76), corresponding to −18.26 kg (95% CI: −19.66 to −16.86)
- BGM0504 15 mg · ae_dc · HKEX filing
BGM0504 注射液治疗 52 周各剂量组因不良事件导致的终止治疗比例分别为 1.7%、1.2%和 0.7%
- BGM0504 10 mg · weight_tp · Results
10 mg: −17.27% (95% CI: −18.67 to −15.88), corresponding to −16.47 kg (95% CI: −17.85 to −15.09)
- BGM0504 10 mg · ae_dc · HKEX filing
BGM0504 注射液治疗 52 周各剂量组因不良事件导致的终止治疗比例分别为 1.7%、1.2%和 0.7%
- BGM0504 5 mg · weight_tp · Results
5 mg: −14.31% (95% CI: −15.69 to −12.93), corresponding to −13.48 kg (95% CI: −14.83 to −12.13)
- BGM0504 5 mg · ae_dc · HKEX filing
BGM0504 注射液治疗 52 周各剂量组因不良事件导致的终止治疗比例分别为 1.7%、1.2%和 0.7%
- BGM0504 5 mg · weight_unsp · Abstract
Mean percentage changes in body weight from baseline to week 24 were -10.68%
- BGM0504 10 mg · weight_unsp · Abstract
Mean percentage changes in body weight from baseline to week 24 were -10.68%
- BGM0504 15 mg · weight_unsp · Abstract
Mean percentage changes in body weight from baseline to week 24 were -10.68%
Registered trials (5)
From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.
| Trial | Indication | Phase | Status | Start → primary completion | n | Result | Registry |
|---|---|---|---|---|---|---|---|
| NCT07743983 · China A Study of BGM0504 in Early T2DM With Obesity | T2D | Phase 3 | recruiting | 2026-09 → 2028-09 | 372 | recruiting | NCT07743983 |
| NCT07064486 A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia | T2D | Phase 3 | active not recruiting | 2025-07 → 2027-04 | 152 | active not recruiting | NCT07064486 |
| NCT06716203 A Study of BGM0504 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise | T2D | Phase 3 | completed | 2025-01 → 2026-08 | 227 | Completed; results not in the atlas yet | NCT06716203 |
| NCT06716216 A Study of BGM0504 in Participants With Type 2 Diabetes | T2D | Phase 3 | completed | 2025-01 → 2026-08 | 553 | Completed; results not in the atlas yet | NCT06716216 |
| NCT06704581 · China A Study of BGM0504 Injection in Participants With Obesity or Overweight | Obesity | Phase 3 | completed | 2024-10 → 2026-03 | 652 | Completed; results not in the atlas yet | NCT06704581 |
Primary sources
- Linong Ji et al. Efficacy and safety of BGM0504 in Chinese patients with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled Phase 3 trial. Abstract LBA 37. EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan. [Session: LBA OP 07 Incretins: more on signalling, trials and real-world evidence]
- BrightGene. 博瑞医药 (688166.SH) 自愿披露关于BGM0504注射液减重适应症III期临床试验数据的公告 (2026-029) [HKEX filing]. 2026-05-05. Available from: http://static.cninfo.com.cn/finalpage/2026-05-06/1225277468.PDF
- EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan. Abstract easd66778.
- Ji L, Yang G, Huang Y, Ding H, Xie D, Jiang X, et al. Effectiveness, Safety and Pharmacokinetics of BGM0504, a Dual GLP-1/GIP Receptor Agonist, in Chinese Adults With Overweight or Obesity Without Diabetes: A Phase 2 Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Obes Metab. 2026. PMID: 42755112.
How to cite this page
Cite the primary publication for any single result; every value above links to it.